Quantitative coronary angiogram analysis: Nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study)

Hypertension

Volumn 45, Issue 6, 2005, Pages 1153-1158

  Shinoda, Eiji ^a   Yui, Yoshiki ^b   Kodama, Kazuhisa ^c   Hirayama, Atsushi ^c   Nonogi, Hiroshi ^d   Haze, Kazuo ^e   Sumiyoshi, Tetsuya ^f   Hosoda, Saichi ^f   Kawai, Chuichi ^g  

^a Rakuyo Hospital   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f SAKAKIBARA HEART INSTITUTE   (Japan)

^g TAKEDA GENERAL HOSPITAL   (Japan)

Author keywords

Angiotensin converting enzyme; Atherosclerosis; Nifedipine

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMLODIPINE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; LACIDIPINE; NIFEDIPINE; NITRATE; QUINAPRIL; RAMIPRIL; SIMVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; FEMALE; HEART RATE; HUMAN; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUANTITATIVE CORONARY ANGIOGRAPHY; SIDE EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASODILATATION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; MULTICENTER STUDIES; NIFEDIPINE; SINGLE-BLIND METHOD; VASODILATOR AGENTS;

EID: 20044385942     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000165677.71421.8c     Document Type: Article

References (21)

1. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda A, Kawai C. Comparison of nifedipine retard with angiotensin-converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) Randomized Trial. Hypertens Res. 2004;27:181-191.
2. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI; on behalf of the REGRESS Study Group Interuniversity Cardiology Institute Utrecht Netherlands. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
3. Mancini GB, Miller ME, Evans GW, Byington R, Furberg CD, Pitt B, PREVENT Study Group. Post hoc analysis of coronary findings from the Prospective Randomized Evaluation of the Vascular Effects of the Norvasc Trial (PREVENT). Am J Cardiol. 2002;89:1414-1416.
4. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, Montague TJ. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000;102:1748-1754.
5. Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS; QUIET Investigators. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Quinapril Ischemic Event Trial. Am J Cardiol. 1999;83:43-47.
6. Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 2001;103:2949-2954.
7. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W; for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
8. Zanchetti A, Bond MG, Hening M, Neiss A, Mancia G, Palu CD, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P; on behalf of the ELSA Investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation. 2002;106:2422-2427.
9. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK; for the SECURE Investigators. Effect of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation. 2001;103:919-925.
10. Zanchetti A, Crepaldi G, Bond G, Gallus G, Veglia M, Mancia G. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of Plague Hypertension Lipid Lowering Italian Study (PHYLLIS). J Hypertens 2003;21(suppl 4):S346.
11. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, Hart H, Scott J, White H. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. Part-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol. 2000;36:438-443.
12. Terpstra WF, May JF, Smit AJ, Graeff PA, Meyboom-de Jong B, Crijns HJ. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens. 2004;22:1309-1316.
13. Mancini GB. Antiatherosclerotic effects of calcium channel blockers. Prog Cardiovasc Dis. 2002;45:1-20.
14. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95:1115-1118.
15. Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, Cianflone D, Sanna T, Sasayama S, Maseri A. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation. 2000;101: 1102-1108.
16. Ozaki Y, Keane D, Serruys PW. Progression and regression of coronary stenosis in the long-term follow-up of vasospastic angina. Circulation. 1995;92:2446-2456.
17. Mancini GBJ, Pitt B; on behalf of the PREVENT Investigation. Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects on Norvasc Trial (PREVENT). Am J Cardiol. 2002;90:776-778.
18. Mason RP. Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine. Am J Cardiol. 2001;88: 2M-6M.
19. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, Dilley RJ, Cooper ME, Allen TJ. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation. 2002;106:246-253.
20. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
21. Nissen SE, Tuzcu EM, Libby P, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. J Am Med Assoc. 2004;292:2217-2226.